	pioglitazone nontoxicity	6.262542395704254
	market generic pioglitazone	5.591932044772897
¡°	TZD compound pioglitazone	5.48354966284311
	pioglitazone improved toxicity	4.4640096161395
	single compound pioglitazone	4.302054364062214
	antidiabetic research	3.7300382809325145
	antidiabetic agent	3.7145879408278137
	antidiabetic treatment	3.7132935546872345
	pyridyl ring	3.0562623777168336
	antidiabetic activity	2.4787662778063457
	antidiabetic composition	2.4734750254336366
	Type diabetes	2.4116733863800683
¡°	certain tzd	2.3631627127148067
	6-ethyl compound	2.2508593626897153
	type diabetes	2.2480236913456095
	insulin sensitizer	2.140090201156232
	insulin receptor	2.026894428991698
	insulin resistance	2.0072476015214846
	first homologation	1.7996849893448967
	ring walking	1.7129281392058566
	glucose transporter	1.6508858889201015
	5-ethyl compound	1.5765174103709017
¡°	TZD market	1.5761801269408429
	effective antidiabetic compound	1.5729843698344963
	namely ethyl substitute pyridyl	1.398601283792548
¡°	ethyl substitute tzd	1.1506029091080836
	Antidiabetic Agents	1.0667201262510093
¡°	prior art tzd compound	1.0350511093030563
	obviousness contention	0.8829522971593169
	obviousness argument	0.8825735611470257
	remain challenge	0.8824895740479164
	first argument	0.8824272385511615
	ethyl substituent	0.690235401582421
¡°	drug ACTOS	0.685287099542486
	Denise Cote	0.6767685055192763
	Diabetes	0.6767685055192763
	Insulin	0.6767685055192763
	thiazolidinedione	0.6767685055192763
	PPARgamma	0.6767685055192763
	blood glucose level	0.6644451178222174
	blood sugar	0.6071669805038399
	4-ethyl compound	0.5629852239565649
	Grabiak	0.5440409901212387
	compound b. left moiety	0.5114845028803895
	Genpharm	0.3903779677499113
	diluent	0.3903779677499113
	3-ethyl compound	0.3753234826377099
	a. Selection	0.3386270662080871
	well activity.3	0.3383939103869279
	Lead Compound	0.33779522749304036
	isomer	0.257316730504914
	known compound	0.23499741129618176
	pharmacologically acceptable carrier	0.2295730121308965
	lead compound	0.22591585235306036
	compound b. information	0.19838591105360037
	structurally similar compound	0.18829805603382074
	pharmacologically acceptable salt	0.18807131189448817
	TSM test	0.18179372981563477
	methyl CH3 group	0.1728417562661622
	nine specific compound	0.16482786896593524
	Ugine	0.16398642342084313
	structurally similar chemical compound	0.1524191612600897
	four possible compound	0.15006547973463577
	compound structure	0.1499717659526961
	know compound	0.14973783148373077
	fifty four compound	0.14893623221792318
	type diabetic individual	0.1372478632702315
	Lalu	0.1361435248467907
	In Deuel	0.13017860038342843
	Dillon	0.12519314877521923
	methyl group	0.12009401069256566
	close prior art compound	0.11295846186437473
	association	0.09647701171773326
	food	0.08347615343599767
	unpatentability	0.08347615343599767
	energy	0.08316171503614746
	broad safety margin	0.08184844722143121
	chemist	0.07925222335555365
	excipient	0.07300224340138767
	analog	0.06440629542729706
	Table	0.05724328267589962
	hundred million	0.04658669157138629
	unfavorable side reaction	0.04443615157127837
	cellular surface	0.038099668953778254
	pharmacological effect	0.03685684499468875
	Paragraph IV certification	0.036081844218366195
	rigid mandatory formula	0.033725286455752033
	normally prima facie case	0.030857213263621876
	enforceability	0.02877433006463223
	launch	0.02862164133794981
	Kansas City	0.025171493046989554
	unexpected result	0.024674029536259686
	KSR Court	0.022615656074840108
	experimental datum	0.022062325229736845
	helpful insight	0.021982999785672617
	body cell	0.021844902241891378
	gross sale	0.021018501770697202
	Jones	0.020877654983990437
	overwhelming evidence	0.02079885714350216
	structural similarity	0.019508144027100598
	body inability	0.018289416674545738
	ANDA	0.017675271714817163
	specific molecular modification	0.017047380152921506
	preliminary finding	0.015728074530944897
	chemical structure	0.015165277467710436
	Hatch Waxman Act	0.0144775927789728
	necessary inconsistency	0.014347484597336814
	improve property	0.014171791353470084
	Prior Art	0.013082741083583219
	similar property	0.012672568736047319
	two obvious chemical change	0.011576863813470497
	rigid application	0.011084066841894958
	Review	0.011047062488564928
	requisite motivation	0.010650471663096565
	inadequate level	0.009846782038483182
	three generic drug manufacturer	0.009666634787101003
	external source	0.008648332177891313
	Lourie	0.008584892507596654
	generic version	0.008154096029166568
	New York	0.00814023103573026
	Claims	0.007743457840074819
	pharmaceutical composition	0.006824316888480413
	main source	0.006616677799023151
	Southern District	0.006478541306534997
	U.S. Food Drug Administration	0.006277660006833936
	Abbreviated New Drug Application	0.0062026510419085894
	three main argument	0.006111618405373404
	patient	0.006013309012625852
	FDA approval	0.0054298681880610294
	thorough well reason opinion	0.0054037505968759355
	nonobviousness	0.0035328889097946087
	propose manufacturer	0.003527529062892191
	active ingredient	0.003491870835150882
	patentable inter alia	0.003386089635193252
	extensive finding	0.0032905794094760118
	close establish structural relationship	0.003069493830452309
	suggestion	0.002771210197689531
	certain evidentiary ruling	0.0025268469256273314
	evidentiary burden	0.002404527978458333
	Teleflex Inc.	0.0021479873100247854
	Chem	0.0018587658136041802
	contrast	0.0015934737442629225
	bench trial	0.0013772314548944013
	factor	0.0012988902511470815
	numerous legal factual determination	0.0012889650395776927
	adequate support	0.00109417277935742
	Indus	0.001072383587049376
	inequitable conduct	0.0010690757744734472
	Supreme Court	0.0010102805252119526
	step	0.0007457418831974956
	January	0.0007220298165836427
	owner	0.000719004169509414
	substantial commercial success	0.0006992545025856829
	September	0.0006871950856995325
	test result	0.000682176612556457
	objective evidence	0.0006278810609111228
	pertinent art	0.0005863489805415951
	critical portion	0.0005430571301708912
	prosecution history	0.0005061614765050881
	obviousness inquiry	0.00045419463908587883
	legal principle	0.00036872999257451714
	particularly law	0.00035333478032705765
	accuse infringer	0.0003372016027746124
	two type	0.0003086601429296738
	merit	0.0002791525182684534
	asserted	0.0002656851040540395
	four available position	0.00026450579505483653
	response	0.00025903455247441897
	another position	0.00023690242105063217
	addition	0.00021283009275407025
	obviousness determination	0.00019945666124101722
	ordinary skill	0.00017912966118218508
	clear convincing evidence	0.00015388815990498772
	common form	0.0001466910487738498
	particular manner	0.00011984611997053027
	relevant field	0.00010875705719294353
	underlie factual question	0.00010846053801628035
	holding	0.00010004310744511035
	respect	7.563269656899748e-05
	district court legal factual ruling	7.465709659696074e-05
	background	6.493515502384378e-05
	difference	6.005591420271688e-05
	en banc decision	5.824422402542136e-05
	Ltd.	4.4803234097127104e-05
	clear error	4.358205010302459e-05
	de novo	3.4042428176944384e-05
	regard	3.2798365711803777e-05
	jurisdiction	2.753912988022345e-05
	invalidity argument	1.775546156294693e-05
	analysis	1.614126183614128e-05
	U.S.C.	1.427097869129052e-05
	suit	1.3913937946868516e-05
	purpose	8.224352071051274e-06
	order	7.146869730726909e-06
	Idaho	6.511529387166261e-06
	scope	6.438418193167526e-06
	light	3.895746079817451e-06
	court determination	3.230237123130934e-06
	prior art subject matter	2.762620673909108e-06
	court conclusion	2.5183985263681115e-06
	allege invention	1.6124816028538755e-06
	reference	1.2773074975002407e-06
	case law	1.221702492562493e-07
	infringement action	4.949502435438252e-08
	judgment	4.364201129516198e-09
	one issue	2.101546771703363e-09
	Appeals	0.0
	Fed	0.0
